ArticleFrontiers in medicine2026
Differential efficacy of Conbercept vs. Ranibizumab on retinal microstructural changes in macular edema secondary to retinal vein occlusion during the loading phase.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare the efficacy of Conbercept vs.Ranibizumab on retinal microstructural changes in patients with retinal vein occlusion-associated macular edema (RVO-ME) by evaluating multidimensional OCT biomarkers during the loading phase. Methods: This retrospective cohort study analyzed treatment-naive RVO-ME patients receiving three monthly intravitreal injections of Conbercept or Ranibizumab. Propensity score matching (PSM) was used to balance baseline characteristics. Inter-group and intra-group comparisons of OCT biomarkers including central macular thickness (CMT), disorganization of the retinal inner layers ([DRIL), hyperreflective dots (HRD), intraretinal fluid (IRF), subretinal fluid (SRF), and ellipsoid zone (EZ) disruption] were performed using the Mann-Whitney Results: After PSM, 108 patients (54 per group) were analyzed. Both agents showed significant improvements in all OCT biomarkers and BCVA at months 1 and 3 compared to baseline (all Conclusions: Conbercept and Ranibizumab showed comparable primary outcomes and subtle divergences in exploratory secondary OCT biomarkers during the loading phase: Conbercept yielded greater DRIL reduction, whereas Ranibizumab achieved lower CMT and IRF at early time points. These preliminary findings may generate hypotheses for an OCT phenotype-driven approach to precision anti-VEGF therapy in RVO-ME.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.